[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
April 1980

Methotrexate Hepatotoxicity in PsoriasisConsideration of Liver Biopsies at Regular Intervals

Author Affiliations

From the Department of Medicine, Sections of Dermatology (Drs Robinson and Baughman) and Gastroenterology/Hepatology (Dr Cimis), Mary Hitchcock Memorial Hospital, Hanover, NH, and the Department of Dermatology, New York University School of Medicine (Dr Auerbach). Dr Robinson is now with the Department of Dermatology, Northwestern University School of Medicine, Chicago.

Arch Dermatol. 1980;116(4):413-415. doi:10.1001/archderm.1980.01640280049016

† Fibrosis of the liver developed to a degree that contraindicated further treatment with methotrexate in 11 of 43 patients who had been receiving maintenance therapy with methotrexate for psoriasis. Liver biopsy had been performed prior to initiation of methotrexate therapy and was repeated at 12- to 18-month intervals. In this retrospective study, age of the patient and duration of therapy have been found to be significant factors in those patients receiving only the weekly oral dosage schedule. Yearly biopsies of the liver are recommended for patients who receive methotrexate throughout their courses of therapy.

(Arch Dermatol 116:413-415, 1980)